key: cord-0782376-8ncc6d2n
authors: Shen, Wei-Bin; Logue, James; Yang, Penghua; Baracco, Lauren; Elahi, Montasir; Reece, E. Albert; Wang, Bingbing; Li, Ling; Blanchard, Thomas G; Han, Zhe; Frieman, Matthew B; Rissman, Robert A; Yang, Peixin
title: SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer’s-like neuropathology
date: 2022-02-03
journal: bioRxiv
DOI: 10.1101/2022.01.31.478476
sha: c18d0ea1f9b9cf9b46f9c5b47eae05d66dd06c1a
doc_id: 782376
cord_uid: 8ncc6d2n

Major cell entry factors of SARS-CoV-2 are present in neurons; however, the neurotropism of SARS-CoV-2 and the phenotypes of infected neurons are still unclear. Acute neurological disorders occur in many patients, and one-third of COVID-19 survivors suffer from “brain diseases”. Here, we show that SARS-CoV-2 invades the brains of five patients with COVID-19 and Alzheimer’s, autism, frontotemporal dementia or no underlying condition by infecting neurons and other cells in the cortex. SARS-CoV-2 induces or enhances Alzheimer’s-like neuropathology with manifestations of β-amyloid aggregation and plaque formation, tauopathy, neuroinflammation and cell death. SARS-CoV-2 infects mature but not immature neurons derived from inducible pluripotent stem cells from healthy and Alzheimer’s individuals through its receptor ACE2 and facilitator neuropilin-1. SARS-CoV-2 triggers Alzheimer’s-like gene programs in healthy neurons and exacerbates Alzheimer’s neuropathology. A gene signature defined as an Alzheimer’s infectious etiology is identified through SARS-CoV-2 infection, and silencing the top three downregulated genes in human primary neurons recapitulates the neurodegenerative phenotypes of SARS-CoV-2. Thus, SARS-CoV-2 invades the brain and activates an Alzheimer’s-like program.

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 112 Because ACE2, the SARS-CoV-2 cellular receptor, and NRP1, a facilitator of SARS-CoV-2 entry, 113 are expressed in CNS neurons, we hypothesized that SARS-CoV-2 can infect neural cells in the brain, 114 especially under conditions such as Alzheimer's disease and autism with BBB compromise. SARS-CoV- 115 2 has been observed in cells of olfactory bulbs. We focused on cognitive centers of the brain. The SARS- 116 CoV-2 spike protein and nucleocapsid protein were detected in cells of the inferior frontal cortexes of five 117 COVID-19 cases: two autism cases, one Alzheimer's case, one frontotemporal dementia (FTD) case and 118 one case without any underlying health conditions (apparently healthy case) (Fig. 1, Fig. S1 ). In contrast, 119 there was no positive staining of spike protein or nucleocapsid protein in the cortexes of the non-COVID-120 19 autism brains (Fig. 1A, C, Fig. S1A ). Spike protein-and nucleocapsid protein-positive viral particles 121 were robustly present in the cytoplasm and cellular projections of cortical cells (Fig. 1E, F) . RNAscope in 122 situ hybridization detected the abundant presence of SARS-CoV-2 genomic RNA in cortical cells of the 123 five COVID-19 cases (Fig. 1G, H; Fig. S1F ). PCR analysis using the CDC method [29] confirmed the 124 presence of SARS-CoV-2 RNA in the three cases that had frozen brain tissues (Fig. 1I ). In the 31-year-125 old COVID-19 autism case, the amounts of SARS-CoV-2 RNA in the inferior frontal cortex and the numbers of SARS-CoV-2 spike protein-positive cells in these three regions were different in these three 134 COVID-19 cases (Fig. 1J, K, L) . These findings demonstrated that SARS-CoV-2 was neurotropic in this 135 cohort of COVID-19 patients (Table S1) .

137 Because SARS-CoV-2 exists in cortical cells in COVID-19 patients, these cells must express ACE2 138 and NRP1. Indeed, the SARS-CoV-2 spike protein staining signal was colocalized with both ACE2 and 139 NRP1 signals ( Fig. 2A, B) , indicating that SARS-CoV-2 infects cortical cells using these proteins. ACE2 To further determine the type of programmed cell death, we examined the presence of necroptotic, 171 ferroptotic, and senescent cells. The cell necroptosis markers phospho-MLKL (mixed lineage kinase 172 domain-like) and phospho-RIPK3 coexisted in spike protein-positive cells (Fig. 3C, Fig. S3D ). Similarly, 173 the two cell ferroptosis markers TfR1 (transferrin receptor) and ASCL4 (long-chain fatty acyl-CoA 174 synthetase 4) were expressed in cells with positive spike protein signals (Fig. 3D, Fig. S3E ). Because the 175 cytokine associated with SARS-CoV-2 may trigger the cellular senescence program, we detected the 176 senescence marker DPP4 (dipeptidyl-peptidase 4) in a subset of spike protein-positive cells (Fig. 3E) .

There were negligible double spike protein-and TfR1-or p-RIPK3-positive cells in the COVID-19 178 Alzheimer's case (Fig. 3D, Fig. S3D ). These findings suggest that SARS-CoV-2 leads to cell death and senescence through multiple pathways. 181 It has been suggested that SARS-CoV-2 infection leads to neuroinflammation. However, direct 182 evidence on the link between SARS-CoV-2 and neuroinflammation is still lacking. The protein expression 183 of two cytokines, IL-1 and IL-6 (interleukin 6), was significantly increased in the cortical cells of NFTs were present in the inferior cortexes of the two COVID-19 autism cases (Fig. 4E ). Cellular p-Tau 199 deposition was induced in these two COVID-19 autism cases and the COVID-19 case without underlying 200 health conditions (Fig. 4E, F) , whereas there were no signals or negligible p-Tau staining signals in the 201 cortexes of non-COVID-19 control brains (Fig. 4E, F ). There were significantly higher numbers of Pick 202 bodies in the COVID-19 FTD case than in age-matched non-COVID-19 FTD cases (Fig. 4G, H) . Thus, 203 SARS-CoV-2 infection is linked to Alzheimer's neuropathology. 205 Based on the above findings in neurons of COVID-19 patients' brain cortexes, we propose that SARS-206 CoV-2 can effectively infect neurons. To establish an in vitro platform to study this process, we obtained 207 iPSCs derived from age-matched healthy individuals and Alzheimer's patients and differentiated it into deposition and NFTs and neuroinflammation in COVID-19 patients, we hypothesized that SARS-CoV-2 226 infection can turn neurons derived from iPSCs from healthy individuals into Alzheimer's-phenotype 227 neurons. Neurons differentiated from iPSCs of healthy individuals and Alzheimer's patients were infected 228 with wild-type SARS-CoV-2 (WA-1 strain [33]) at an MOI of 0.1 for 48 hours (Fig. 6, Fig. S6 ). SARS- An early study showed no evidence of SARS-CoV-2 infection of neurons [40] . In iPSC-derived 302 brain organoids, SARS-CoV-2 infects only mature choroid plexus cells, not neurons or glial cells [40] . 303 This discrepancy may be due to the different developmental stages of neurons. We show that iPSC-derived 304 immature neurons do not express ACE2 and NPR1 and thus are not able to be infected by SARS-CoV-2, 305 whereas mature neurons do express these two SARS-CoV-2 receptors and are infected by this virus. infected immune cells into the brain has been proposed as a potential CNS entry route [14] . In agreement 319 with a prior report, no sign of infected immune cell infiltration into COVID-19 autism patients' brains was 320 found in the present study. Immune cells were present in the cortex in the COVID-19 Alzheimer's case.

Thus, BBB leakage may be the major CNS entry route for SARS-CoV-2 into autism brains. disease observed in individuals exposed to SARS-CoV-2.

The pathogenesis of Alzheimer's disease contains an element of infectious disease pathogenesis. cells.

The major source for postmortem tissues is the Brain and Tissue Bank at University of Maryland (UMB). The Brain and Tissue Bank is a brain and tissue repository of the NIH NeuroBioBank.

The Brain Tissue Bank is a national resource for investigators utilizing human post-mortem brain tissues and related biospecimens for research in understanding the conditions of the nervous system. All brain tissue is procured, stored, and distributed according to applicable State and Federal guidelines and regulations involving consent, protection of human subjects and donor anonymity. All brain tissues we obtained from the Brain Tissue Bank are de-identified.

Following formalin-fixed brain tissues were obtained from the Brain and Tissue Bank at UMB: Following frozen brain tissues were also obtained from the Brain and Tissue Bank. The frozen tissues were used for RNA extraction followed by reverse transcription and PCR detection of SARS-CoV-2 with CDC specific primers. The frozen tissues include SARS-CoV-2 infected lung and brain tissues (ASD, #6436), age-matched non-COVID-19 ASD controls and FTD controls.

In addition, paraffin sections and frozen brain tissues of the subjects of COVID-19 FTD (1 case) and COVID-19 individual without underlying condition, and non-COVID-19 AD (3 cases) were obtained from the Biomarker Laboratory and Biorepository at University of Southern California

Alzheimer's Therapeutic Research Institute (USC ATRI) at University of California San Diego (UCSD).

Primary Human Neurons were obtained from Neuromics (CA3 Bioscience, MN, USA). The cells were maintained in neuron growth medium supplemented (CA3 Bioscience, MN, USA) with 10% FBS at 37 °C in a humidified atmosphere of 5% CO2 in culture flask.

The formalin-fixed brain tissue blocks were immersed in 30% sucrose, then embed in OCT cryostat sectioning medium. The tissues were sectioned on a cryostat at 10 μm. After rehydrated, the sections were treated with 2% H2O2 for 15 minutes to quench the endogenous peroxidase. The staining was performed as previously described [1, 2] . 

β-amyloid (A) and phospho-tau (pTau) Immunohistochemistry was carried out as previously described [3] . Briefly, the coronal sections were rehydrated, and endogenous peroxidase was quenched by treating with 0.3% H2O2. For A staining, the antigen retrieval was carried by using 70% formic acid for 20 minutes. Antigen retrieval for the other antibodies was by autoclaving at 120C for 5 min. The primary antibody was applied on the sections at 4C overnight, followed by 60-min incubation with specific secondary antibody coupled with HRP (Histofine simple stain MaxPo M/R, Nichirei Bioscience Inc., Japan) at room temperature. DAB reaction was performed to visualize the color. All antibody dilutions and washing steps were performed in phosphate buffer, pH 7.

Cortex) in three sections/slices from each group were measured using the ImageJ Fiji platform.

Data were represented as staining intensity per square millimeter. Because the MaxPo M/R antibodies are Fab fragments, the blocking is not necessary.

The Aβ staining Thioflavin-T were performed following the similar antigen protocol. After blocking with 5% goat serum for 30 minutes overnight incubation with anti Aβ antibody 6E10 were performed. In the following day the brain sections were probed with Alexa-fluor594 labeled secondary antibody. After an extensive washing, Thioflavin-T (0.1% in 50% DMSO) were applied over the brain sections for 5 minutes. An extensive washing was performed using PBS containing 0.05% tween20. Furthermore, the fluorescent background was quenched with Tureblack (Biotium, USA). Thioflavin-T and Alexa-fluor594 intensity were measured using a fluorescence laser microscope (LSM780, Zeiss, Germany).

For immunofluorescence staining, cells were cultured on a collagen-coated coverslip. After specific treatments, cells were fixed with 4% paraformaldehyde-PBS. The cell membrane was permeabilized with 0.25% Triton-X100 and/or 5 mg/ml digitonin followed by blocking with 5%

BSA. After probing with primary antibodies, specific Alexa-fluor labeled secondary antibody were used. 4',6-Diamidino-2-phenylindole dihydrochloride (DAPI) staining was used to visualize the nuclei (Thermo Fisher Scientific). Fluorescence was assessed using a fluorescence laser microscope (LSM780, Zeiss, Germany).

RNA In situ hybridization in FFPE slides was performed by using the RNAScope 2. min. Subsequently, the signals were detected by incubating with a mixture of RED-B and RED-A at ratio of 1:60 for 10 min at room temperature followed by counterstaining with 50% hematoxylin for 2 min.

Human fibroblast from Coriell Institute were induced into pluripotent stem cell with CMV spheres were transferred to wells coated with Matrigel (BD Biosciences) and grown in NPM medium which is same to NIM medium but replace SB431542 and LDN-193189 with 10 ng/ml bFGF (PeproTech), 10 ng/mL epidermal growth factor (EGF) (PeproTech), and 2 µg/ml heparin (Sigma). On day 15, medium was changed to NDM medium which is same to NPM medium but replace bFGF, EGF and heparin in NPM with brain-derived neurotrophic factor (10 ng/ml; PeproTech), and glial cell-derived growth factor (10 ng/ml; PeproTech). Around day 20, neurons were observed and were further differentiated for 30 days.

Neurons derived from AD or Control (from healthy individuals) hiPSCs with or without SARS-CoV-2 infection were fixed in 4% paraformaldehyde (PFA) for 10 minutes followed by blocking in 5% bovine serum albumin in PBST (0.1% Triton X-100 in PBS) for 10 minutes. The 

VeroE6 cells were plated in 12 well plates with 2x10 5 cells per well one day prior to processing.

On the day of processing, samples were serially diluted 1:10 and 200uL of each sample dilution was added to each well in singlet and incubated for 1 hour at 37°C (5% CO2) with rocking every 15 minutes. Following incubation, 2 mL of a semi-solid agar overlay, DMEM (gibco) containing 4% fetal bovine sera (gibco) and 2% agarose, was added to each well. Plates are incubated for 3 days at 37°C (5% CO2) before plates were fixed with 4% paraformaldehyde, stained with crystal violet stain, and plaques counted.

Primary Human Neurons obtained from Neuromics (Edina, MN) grow for four weeks in the Neuromics growth medium supplemented with brain derived neurotropic factor (BDNF). Medium were changed every 2 days. For further experiment, cells were plated on a 6-well plate in neuron growth medium supplemented with 5% FBS. siRNA transfection was carried out using X-tremeGENE siRNA transfection reagent (Roche, Basel, Switzerland) at 60% cell confluency.

Medium was replaced with fresh medium 24 hours post-transfection and maintained for additional 48 hours. Lentivirus mediated overexpression of the FCGR, LILRB5 and OTOR carried out using virus particles obtained from OriGene (Rockville, MD). Virus transduction were carried out at 5.0 MOI using polybrene. GFP expressing lenti-particles were used as the control.

mRNAs were extracted from neurons derived from AD or Control hiPSCs with or without SARS-CoV-2 infection and sequenced at BGI on DNBSeq platform. Briefly, mRNAs were extracted with Trizol reagent. First-strand cDNA was generated using random hexamer-primed reverse transcription, followed by a second-strand cDNA synthesis. The synthesized cDNA was subjected to end-repair and then was 3' adenylated. Adapters were ligated to the ends of these 3' adenylated cDNA fragments, followed by PCR. PCR products were purified with Ampure XP Beads and dissolved in EB solution. Library was validated on the Agilent Technologies 2100 bioanalyzer.

The double stranded PCR products were heat denatured and circularized by the splint oligo sequence. The single strand circle DNA were formatted as the final library. The library was amplified with phi29 to make DNA nanoball (DNB) which had more than 300 copies of one molecular. The DNBs were load into the patterned nanoarray and single end 50 (pair end 100) bases reads were generated in the way of sequenced by synthesis.

mRNAs were extracted from neurons derived from AD or Control hiPSCs with or without SARS-CoV-2 infection in Trizol reagent (Thermofisher, Waltham, MA) and followed by cDNA synthesis with SuperScript™ III Reverse Transcriptase kit (ThermoFisher). RT-PCR were performed with PowerUp™ SYBR™ Green Master Mix (ThermoFisher) with 45 cycles and PCR products were loaded into 2% agarose gel and run at 75 v for 5.5 h. Gel Image were recorded with Bio-Rad ChemiDoc MP imaging system (Hercules, CA).

In the experiment assessing the impact of SARS-CoV-2 virus on the brain pathology, we analyzed (a) 5 Covid19 samples consisting of AD-Covid19 (1 case), FTD-Covid19 (1 case), ASD-Covid19 (2 cases), and Covid-19 without underlying condition (1 case); (b) 6 cases of sporadic AD as the controls; and (c) 8 cases of age-matched, non-Covid-19 healthy controls. Labeled cells from at least 3 random fields (n ≥ 3) were counted. Data are presented as the means ± standard errors (SEs).

Student's t test was used for two group comparisons. One-way ANOVA was performed for comparisons of more than two group using graphPad prism software v7. In ANOVA, a Tukey test was used to estimate the significance between groups. Differences were considered statistically significant when P < 0.05.

In the experiment with cell culture studies, we differentiated neurons from 3 iPSC lines derived from AD fibroblast cells and 3 lines from healthy subjects as the controls. The experiments were repeated in triplicate as we previously described [4, 5] . Data are presented as the means ± standard errors (SEs). Student's t test was used for two group comparisons. One-way ANOVA plus Tukey test was performed for comparisons of more than two group. Differences were considered statistically significant when P < 0.05. 

Neurologic Manifestations of Hospitalized Patients With Coronavirus 594 Disease

The chronic neuropsychiatric sequelae 596 of COVID-19: The need for a prospective study of viral impact on brain functioning

6-month neurological and psychiatric outcomes in 236 379 598 survivors of COVID-19: a retrospective cohort study using electronic health records

SARS-CoV-2: A new virus but a familiar inflammation brain pattern

Middle East Respiratory Syndrome 601

Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4

Severe acute respiratory syndrome coronavirus infection causes 604 neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Olfactory transmucosal SARS-CoV-2 invasion as 606 a port of central nervous system entry in individuals with COVID-19

Multiorgan and Renal Tropism 608 of SARS-CoV-2

Neuroinvasion of SARS-CoV-2 in human and 610 mouse brain

COVID-19 treatments and pathogenesis 612 including anosmia in K18-hACE2 mice

Alzheimer's disease: A matter of blood-brain barrier dysfunction?

Blood-brain barrier and intestinal epithelial 616 barrier alterations in autism spectrum disorders

Effects of COVID-19 on the Nervous System

SARS-CoV-2 Cell Entry Depends on 619 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing 621

Earlier Virus Detection

Neuropilin-1 facilitates SARS-CoV-2 623 cell entry and infectivity

Neuropilin-1 expression in GnRH neurons regulates 625 prepubertal weight gain and sexual attraction

Psychiatric and neuropsychiatric presentations 627 associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 628 pandemic

Neurological and neuropsychiatric 630 complications of COVID-19 in 153 patients: a UK-wide surveillance study

The emerging spectrum of COVID-19 632 neurology: clinical, radiological and laboratory findings

A case of COVID-19 infection presenting 634 with a seizure following severe brain edema

Delirium as a presenting feature in COVID-19: 636 Neuroinvasive infection or autoimmune encephalopathy?

A Unique Presentation of Delirium 638 in a Patient with Otherwise Asymptomatic COVID-19

Frequency and profile of objective 640 cognitive deficits in hospitalized patients recovering from COVID-19

Immediate and long-term consequences of COVID-19 infections 642 for the development of neurological disease

SARS-CoV-2 pathophysiology and 644 assessment of coronaviruses in CNS diseases with a focus on therapeutic targets

COVID-19 and dementia: Analyses of risk, disparity, and outcomes from electronic 647 health records in the US

SARS-CoV-2 detection and genomic 649 sequencing from hospital surface samples collected at UC Davis

Neuronal loss correlates with but exceeds 651 neurofibrillary tangles in Alzheimer's disease

Tangle and neuron numbers, but not 653 amyloid load, predict cognitive status in Alzheimer's disease

SARS-CoV-2 Reverse Genetics Reveals 655 a Variable Infection Gradient in the Respiratory Tract

SARS-CoV-2 spike glycoprotein vaccine candidate 657 NVX-CoV2373 immunogenicity in baboons and protection in mice

Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus

A 3D human brain-like tissue model of herpes-662 induced Alzheimer's disease

Neuroinvasion by human respiratory coronaviruses

Infectability of human BrainSphere 667 neurons suggests neurotropism of SARS-CoV-2

SARS-CoV-2 infects human neural progenitor cells and brain 669 organoids

SARS-CoV-2 Infects the Brain Choroid Plexus 671 and Disrupts the Blood-CSF Barrier in Human Brain Organoids

Anti-SARS-CoV-2 antibodies 673 in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients

The SARS-CoV-2 spike protein 676 alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier

Human Pluripotent Stem Cell-Derived Neural Cells 679 and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium

SARS-CoV-2 targets neurons 682 of 3D human brain organoids

Virus-induced senescence is driver and 684 therapeutic target in COVID-19

Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating 686 BACE1 gene expression

A SARS-CoV-2 protein interaction map reveals 688 targets for drug repurposing

Environmental neurotoxin-induced progressive model of parkinsonism in rats

Cell-Based Therapy in TBI: Magnetic Retention of Neural Stem Cells In Vivo

Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice

Maternal diabetes induces senescence and neural tube defects sensitive to the senomorphic rapamycin

Ask1 gene deletion blocks maternal diabetes-induced endoplasmic reticulum stress in the developing embryo by disrupting the unfolded protein response signalosome

Resource Tables